Behavioral Health Systems Baltimore, Baltimore, MD, United States of America.
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, United States of America.
J Subst Abuse Treat. 2022 Dec;143:108895. doi: 10.1016/j.jsat.2022.108895. Epub 2022 Oct 1.
Rates of hospitalizations from medical complications of opioid use disorder (OUD) are rising and many of these patients require post-acute care at skilled nursing facilities (SNFs). However, access to medication for OUD (MOUD) at SNFs remains low and patients with OUD have high rates of patient-directed discharge (PDD) and hospital readmissions.
Opioid Use Disorder Medical Patient Engagement, Enrollment in treatment and Transitional Supports (OUD MEETS) program was a clinical pilot designed to increase initiation of buprenorphine and methadone for hospitalized patients with OUD requiring post-acute care. The program comprises a hospital partnership with two SNFs and two opioid treatment programs (OTPs) to improve recovery supports and access to MOUD for patients discharged to SNF.
Between August 2019 and August 2020, study staff approached 49 hospitalized patients with OUD for participation in OUD MEETS. Twenty-eight of 30 eligible patients enrolled in the program and initiated buprenorphine or methadone. Twenty-seven (96 %) enrolled patients successfully completed hospital treatment. Twenty-three (85 %) patients successfully completed medical treatment at SNF. Thirteen (46 %) enrolled patients had confirmed linkage to OUD treatment post-SNF. One patient left the hospital (4 %) and four patients left SNF (15 %) via PDD.
OUD MEETS demonstrates feasibility of hospital, SNF, and OTP partnership to integrate MOUD treatment into SNFs, with high rates of completion of medical treatment and low rates of PDD. Future research should find sustainable ways to improve access to MOUD at post-acute care facilities, including through regulatory and policy changes.
由于阿片类药物使用障碍(OUD)的医疗并发症导致的住院率正在上升,许多此类患者需要在康复护理机构(SNF)接受后续护理。然而,SNF 中提供阿片类药物使用障碍治疗药物(MOUD)的机会仍然很低,且患有 OUD 的患者具有较高的患者导向出院(PDD)和医院再入院率。
阿片类药物使用障碍医疗患者参与、治疗和过渡支持(OUD MEETS)计划是一项临床试点项目,旨在增加因需要后续护理而住院的 OUD 患者开始接受丁丙诺啡和美沙酮治疗的机会。该项目由与两家 SNF 和两家阿片类药物治疗项目(OTP)的医院合作组成,旨在改善康复支持,并为转至 SNF 的患者提供获得 MOUD 的机会。
在 2019 年 8 月至 2020 年 8 月期间,研究人员联系了 49 名患有 OUD 的住院患者,以评估他们参与 OUD MEETS 计划的意愿。符合条件的 30 名患者中有 28 名参加了该项目并开始接受丁丙诺啡或美沙酮治疗。27 名(96%)入组患者成功完成了医院治疗。23 名(85%)患者成功完成了 SNF 医疗治疗。13 名(46%)入组患者在 SNF 后成功与 OUD 治疗机构建立了联系。1 名患者(4%)离开医院,4 名患者(15%)通过 PDD 离开 SNF。
OUD MEETS 表明医院、SNF 和 OTP 之间建立合作伙伴关系以将 MOUD 治疗纳入 SNF 是可行的,患者完成医疗治疗的比例很高,PDD 率很低。未来的研究应寻找可持续的方法来改善康复护理机构获得 MOUD 的机会,包括通过监管和政策改革。